A potent neuromedin U receptor 2-selective alkylated peptide. 2017

Naoki Nishizawa, and Yoko Kanematsu-Yamaki, and Masaaki Funata, and Hiroaki Nagai, and Ayako Shimizu, and Hisashi Fujita, and Junichi Sakamoto, and Shiro Takekawa, and Taiji Asami
Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd, Fujisawa 251-8555, Japan. Electronic address: naoki.nishizawa@takeda.com.

Neuromedin U (NMU) mediates various physiological functions via NMUR1 and NMUR2 receptors. NMUR2 has been considered a promising treatment option for diabetes and obesity. Although NMU-8, a shorter peptide, has potent agonist activity for both receptors, it is metabolically unstable. Therefore, NMU-8 analogs modified with long-chain alkyl moieties via a linker were synthesized. An octadecanoyl analog (17) with amino acid substitutions [αMePhe19, Nle21, and Arg(Me)24] and a linker [Tra-γGlu-PEG(2)] dramatically increased NMUR2 selectivity, with retention of high agonist activity. Subcutaneous administration of 17 induced anorectic activity in C57BL/6J mice. Owing to its high metabolic stability, 17 would be useful in clarifying the physiological role and therapeutic application of NMU.

UI MeSH Term Description Entries
D008297 Male Males
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D004435 Eating The consumption of edible substances. Dietary Intake,Feed Intake,Food Intake,Macronutrient Intake,Micronutrient Intake,Nutrient Intake,Nutritional Intake,Ingestion,Dietary Intakes,Feed Intakes,Intake, Dietary,Intake, Feed,Intake, Food,Intake, Macronutrient,Intake, Micronutrient,Intake, Nutrient,Intake, Nutritional,Macronutrient Intakes,Micronutrient Intakes,Nutrient Intakes,Nutritional Intakes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000478 Alkylation The covalent bonding of an alkyl group to an organic compound. It can occur by a simple addition reaction or by substitution of another functional group. Alkylations
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001067 Appetite Depressants Agents that are used to suppress appetite. Anorectic,Anorectic Agent,Anorectics,Anorexic Drug,Anorexigenic Drug,Appetite Depressant,Appetite Suppressant,Appetite Suppressants,Appetite-Depressing Drug,Appetite-Suppressant Drug,Anorectic Agents,Anorexic Drugs,Anorexigenic Drugs,Appetite-Depressing Drugs,Appetite-Suppressant Drugs,Agent, Anorectic,Agents, Anorectic,Appetite Depressing Drug,Appetite Depressing Drugs,Appetite Suppressant Drug,Appetite Suppressant Drugs,Depressant, Appetite,Depressants, Appetite,Drug, Anorexic,Drug, Anorexigenic,Drug, Appetite-Depressing,Drug, Appetite-Suppressant,Drugs, Anorexic,Drugs, Anorexigenic,Drugs, Appetite-Depressing,Drugs, Appetite-Suppressant,Suppressant, Appetite,Suppressants, Appetite
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

Naoki Nishizawa, and Yoko Kanematsu-Yamaki, and Masaaki Funata, and Hiroaki Nagai, and Ayako Shimizu, and Hisashi Fujita, and Junichi Sakamoto, and Shiro Takekawa, and Taiji Asami
August 2022, ACS bio & med chem Au,
Naoki Nishizawa, and Yoko Kanematsu-Yamaki, and Masaaki Funata, and Hiroaki Nagai, and Ayako Shimizu, and Hisashi Fujita, and Junichi Sakamoto, and Shiro Takekawa, and Taiji Asami
May 2020, Bioorganic & medicinal chemistry,
Naoki Nishizawa, and Yoko Kanematsu-Yamaki, and Masaaki Funata, and Hiroaki Nagai, and Ayako Shimizu, and Hisashi Fujita, and Junichi Sakamoto, and Shiro Takekawa, and Taiji Asami
March 2024, ACS medicinal chemistry letters,
Naoki Nishizawa, and Yoko Kanematsu-Yamaki, and Masaaki Funata, and Hiroaki Nagai, and Ayako Shimizu, and Hisashi Fujita, and Junichi Sakamoto, and Shiro Takekawa, and Taiji Asami
August 2007, Pain,
Naoki Nishizawa, and Yoko Kanematsu-Yamaki, and Masaaki Funata, and Hiroaki Nagai, and Ayako Shimizu, and Hisashi Fujita, and Junichi Sakamoto, and Shiro Takekawa, and Taiji Asami
January 2018, European journal of medicinal chemistry,
Naoki Nishizawa, and Yoko Kanematsu-Yamaki, and Masaaki Funata, and Hiroaki Nagai, and Ayako Shimizu, and Hisashi Fujita, and Junichi Sakamoto, and Shiro Takekawa, and Taiji Asami
December 2022, Nature communications,
Naoki Nishizawa, and Yoko Kanematsu-Yamaki, and Masaaki Funata, and Hiroaki Nagai, and Ayako Shimizu, and Hisashi Fujita, and Junichi Sakamoto, and Shiro Takekawa, and Taiji Asami
July 2009, Endocrinology,
Naoki Nishizawa, and Yoko Kanematsu-Yamaki, and Masaaki Funata, and Hiroaki Nagai, and Ayako Shimizu, and Hisashi Fujita, and Junichi Sakamoto, and Shiro Takekawa, and Taiji Asami
July 2000, The Journal of biological chemistry,
Naoki Nishizawa, and Yoko Kanematsu-Yamaki, and Masaaki Funata, and Hiroaki Nagai, and Ayako Shimizu, and Hisashi Fujita, and Junichi Sakamoto, and Shiro Takekawa, and Taiji Asami
December 2003, Journal of neurochemistry,
Naoki Nishizawa, and Yoko Kanematsu-Yamaki, and Masaaki Funata, and Hiroaki Nagai, and Ayako Shimizu, and Hisashi Fujita, and Junichi Sakamoto, and Shiro Takekawa, and Taiji Asami
April 2013, American journal of physiology. Endocrinology and metabolism,
Copied contents to your clipboard!